Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832152 | 0.81 | PPID (0.43) | ALDH1A1SMN1; SMN2CYP2D6CYP2C9PPID | |
| SCHEMBL15832164 | 0.78 | PRMT6 (0.45) | ALDH1A1PRMT6SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL15832158 | 0.74 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL15832188 | 0.73 | ADRB2 (0.35) | ALDH1A1PPIDCHRM3 | |
| SCHEMBL15832176 | 0.71 | EPHX1 (0.46) | SMN1; SMN2PPID | |
| SCHEMBL12643952 | 0.71 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2PPIDCHRM3 | |
| SCHEMBL15832191 | 0.71 | CTSD (0.40) | CYP2D6PPIDCYP2C19 | |
| SCHEMBL14313947 | 0.71 | PRMT6 (0.65) | ALDH1A1PRMT6SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL13293921 | 0.71 | CYP2D6 (0.57) | ALDH1A1PRMT6SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL11192726 | 0.70 | PRMT6 (0.78) | ALDH1A1PRMT6SMN1; SMN2TDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | ALDH1A1 3684/4885PRMT6 1455/4885SMN1; SMN2 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.